• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

10
3
3
3
1

COUNTRY

3
1

PRICE

0
2
9
37

PUBLISHED

0
0
6
37

PRODUCT TYPE

36
1

Ovarian Cancer

(37 Products)

Far less common than breast cancer, but with a higher mortality rate, sufferers of ovarian cancer are experiencing significant unmet needs. There are therefore considerable market opportunities for drug designers and manufacturers in this life-saving sector of the pharmaceutical industry. In this section a host of cutting edge reports provide valuable insight into key markets such as China and the US, the latest drug development activities and the market trends (including sales, pricing and forecasts) for specific drugs like Doxil, Caelyx, Yondelis and Paclitaxel. You can also purchase reports that feature the latest strategies of major and niche industry players such as Alza Corporation, Amgen, Bristol-Myers Squibb, Cell Therapeutics, Genentech, GlaxoSmithKline, Immunogen, Ivax, OSI Pharmaceuticals and Raven Biotechnologies.
Show Less
Read more

PRODUCT TITLE

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

This report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment...

January 2015
FROM
Ovarian Cancer Drug Pathway Analyzer 2015 Ovarian Cancer Drug Pathway Analyzer 2015 - Product Thumbnail Image

Ovarian Cancer Drug Pathway Analyzer 2015

Extra value: One year of free online updates included with this product There are today at least 349 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways...

January 2015
FROM
Ovarian Cancer Drug Pipeline Update 2015 Ovarian Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Update 2015

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for...

January 2015
FROM
Ovarian Cancer Pipeline Highlights - 2015 Ovarian Cancer Pipeline Highlights - 2015 - Product Thumbnail Image

Ovarian Cancer Pipeline Highlights - 2015

The latest report Ovarian Cancer Pipeline Highlights – 2015, provides most up-to-date information on key pipeline molecules in the global Ovarian Cancer market. It covers emerging therapies for Ovarian...

November 2014
FROM

Global Ovarian Cancer Market 2014-2018

About Ovarian Cancer and its therapy Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological...

June 2014
FROM

Ovarian Cancer Treatment Drugs Markets in China

China's demand for Ovarian Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

June 2014
FROM

Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease...

May 2014
FROM
Disease and Therapy Review: Ovarian Cancer Disease and Therapy Review: Ovarian Cancer - Product Thumbnail Image

Disease and Therapy Review: Ovarian Cancer

The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information...

August 2013
FROM
Disease and Therapy Review: Ovarian Cancer Disease and Therapy Review: Ovarian Cancer - Product Thumbnail Image

Disease and Therapy Review: Ovarian Cancer

The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information...

August 2013
FROM

Ovarian Cancer Pipeline Analysis

“Ovarian Cancer Pipeline Analysis” gives a comprehensive insight into the various drug profiles being developed for the treatment of Ovarian Cancer This research report covers all the ongoing drug development...

August 2013
FROM
Global Ovarian Cancer Pipeline Capsule - 2013 Global Ovarian Cancer Pipeline Capsule - 2013 - Product Thumbnail Image

Global Ovarian Cancer Pipeline Capsule - 2013

Fore Pharma's latest report ‘Global Ovarian Cancer Pipeline Capsule – 2013' provides up-to-date information on key Research and Development (R&D) activities in the global ovarian cancer market It covers...

April 2013
FROM
Ovarian Cancer - Pipeline Review, H2 2012 Ovarian Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H2 2012

Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2012
FROM
Metastatic Ovarian Cancer - Pipeline Review, H2 2012 Metastatic Ovarian Cancer - Pipeline Review, H2 2012 - Product Thumbnail Image

Metastatic Ovarian Cancer - Pipeline Review, H2 2012

Metastatic Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline....

October 2012
FROM
Global Ovarian Cancer Drugs Market 2011-2015 Global Ovarian Cancer Drugs Market 2011-2015 - Product Thumbnail Image Special Offer Sale Banner

Global Ovarian Cancer Drugs Market 2011-2015

TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13 1 percent over the period 2011-2015 One of the key factors contributing to this market growth is the increasing...

August 2012
FROM

Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales...

January 2012
FROM
Vargatef (Ovarian Cancer) - Analysis and Forecasts to 2020 Vargatef (Ovarian Cancer) - Analysis and Forecasts to 2020 - Product Thumbnail Image

Vargatef (Ovarian Cancer) - Analysis and Forecasts to 2020

Vargatef (Ovarian Cancer) – Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020” provides Vargatef sales forecasts...

September 2011
FROM
Recentin (Ovarian Cancer) - Analysis And Forecasts to 2020 Recentin (Ovarian Cancer) - Analysis And Forecasts to 2020 - Product Thumbnail Image

Recentin (Ovarian Cancer) - Analysis And Forecasts to 2020

Recentin (Ovarian Cancer) – Analysis And Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Recentin (Ovarian Cancer) – Analysis and Forecasts to 2020” provides Recentin sales estimates...

September 2011
FROM

Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020

Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Farletuzumab sales...

September 2011
FROM

Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Karenitecin sales...

September 2011
FROM

Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020

Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, "Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Carboplatin sales...

September 2011
FROM
Loading Indicator

Our Clients

Almac Diagnostics Group Pfizer, Inc. Astrazeneca PLC Hologic Corporation Roche Diagnostics Ltd. Bristol-Myers Squibb